PharmaResearch Co Ltd banner
P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 333 000 KRW 5.05% Market Closed
Market Cap: ₩3.5T

Gross Margin

76.1%
Current
Improving
by 3.2%
vs 3-y average of 72.9%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
76.1%
=
Gross Profit
₩377.4B
/
Revenue
₩496B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
76.1%
=
Gross Profit
₩377.4B
/
Revenue
₩496B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
PharmaResearch Co Ltd
KOSDAQ:214450
3.3T KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
407.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
197.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
178.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.4B USD
Loading...
AU
CSL Ltd
ASX:CSL
70.3B AUD
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
NL
argenx SE
XBRU:ARGX
37.8B EUR
Loading...

Market Distribution

Higher than 94% of companies in Korea
Percentile
94th
Based on 2 511 companies
94th percentile
76.1%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

PharmaResearch Co Ltd
Glance View

Market Cap
3.5T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

PharmaResearch Co Ltd Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
76.1%
=
Gross Profit
₩377.4B
/
Revenue
₩496B
What is PharmaResearch Co Ltd's current Gross Margin?

The current Gross Margin for PharmaResearch Co Ltd is 76.1%, which is above its 3-year median of 72.9%.

How has Gross Margin changed over time?

Over the last 3 years, PharmaResearch Co Ltd’s Gross Margin has increased from 71.5% to 76.1%. During this period, it reached a low of 71% on Sep 30, 2024 and a high of 76.1% on Sep 30, 2025.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett